RespireRx Pharmaceuticals Inc. Announces $2 Million Funding Commitment Allowing Option Exercise with UWM Research Foundation, Inc. and Entry into a License Agreement for GABA(A) Receptor Allosteric Neuromodulator Intellectual Property
August 04, 2020 08:45 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), has historically been and remains a leader in the research and...
RespireRx Pharmaceuticals Inc. Announces Extension to Long-Term Employment Contract with Tim Jones as President and Chief Executive Officer
August 03, 2020 15:11 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC: RSPI) (“RespireRx” or the “Company”), is pleased to announce that today, Mr. Tim Jones and RespireRx have...
RespireRx Pharmaceuticals Inc. Announces Appointment of Timothy Jones as President and Chief Executive Officer
May 06, 2020 09:25 ET
|
RespireRX Pharmaceuticals Inc.
Dr. Arnold S. Lippa, Ph.D. to Continue as Executive Chairman of the Board of Directors and Chief Scientific Officer Glen Rock, N.J., May 06, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc....
RespireRx Pharmaceuticals Inc. Announces Entry into Option Agreement to License GABA(A) Receptor Allosteric Neuromodulator Intellectual Property from the UWM Research Foundation, Inc.
March 04, 2020 09:00 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., March 04, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of ampakines for a variety...
RespireRx Pharmaceuticals Inc. CEO Issues Progress and Status Report
February 12, 2020 09:15 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Feb. 12, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI), a leader in the development of medicines for respiratory disorders and central nervous system (“CNS”)...
RespireRx Pharmaceuticals Inc. Announces the Filing of Broad Enabling Cannabinoid Continuation-in-Part and New Provisional Patent Applications
February 05, 2020 09:00 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Feb. 05, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of cannabinoids for the...
RespireRx Pharmaceuticals Inc. Announces Appointment of Tim Jones to its Board of Directors
February 03, 2020 09:00 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J, Feb. 03, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of cannabinoids for the...
RespireRx Pharmaceuticals Inc. Executives Participating in the 2nd Annual International Cannabinoid Derived Pharmaceuticals Summit
September 09, 2019 17:13 ET
|
RespireRX Pharmaceuticals Inc.
September 10 – 12, 2019 Workshops, September 10, 2019 Aloft Boston Seaport District 401-403 D. St., Boston, MA 02210 Executive Chairman/CSO/Interim CEO...
RESPIRERX PHARMACEUTICALS INC. SEND NOTICE LETTER TO THE BOARD OF DIRECTORS OF THERAPIX BIOSCIENCES LTD.
July 30, 2019 09:00 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., July 30, 2019 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of cannabinoids for the...
RespireRx Pharmaceuticals Inc. and Impression Healthcare Limited Announce Agreement to Explore Commercialization of Dronabinol for the Treatment of Obstructive Sleep Apnea (OSA) in Australia, New Zealand and Southeast Asia
February 19, 2019 08:50 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Feb. 19, 2019 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of cannabinoids for the...